5th Binaytara Precision Oncology Summit: Redefining Cancer Treatment with Molecular Targeted Strategies (10.25 Credits)
InterContinental San Francisco
888 Howard Street, San Francisco, CA, United States
October 24, 2025 - October 25, 2025
Shivaani Kummar, MD
Oregon Health & Science University
Faculty
Financial Disclosure
Incyte, SillaJen Inc., Deciphera Pharmaceuticals LLC, Moderna Inc, AstraZeneca LP, Immunitas Therapeutics, Inc., Transcenta Therapeutics, Inc., Bristol Myers Squibb, Adanate, Inc., 23andMe Inc., Gilead Sciences Inc., DOT Therapeutics-1 Inc., PMV Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., Blueprint Medicines Corp., Parabilis Pharmaceuticals, Nuvectis Pharma, Inc.
Researcher
PATHOMIQ (co-founder), Fortress Biotech, Inc (equity), Sift Biosciences (Equity)
Ownership_interest
Springworks Therapeutics, SeaGen, Bayer, Genome & Company, HarbourBiomed, BPGbio Therapeutics, Oxford Biotherapeutics, Mundibiopharma, BPGbio, Inc., Gilead, Mirati; GI Innovation Inc, XYone Therapeutics, Genome Insight, Aadi Biosciences, MOMA Therapeutics, Daiichi Sankyo, Parabilis, Boehringer Ingelheim Pharmcaeuticals
Consultant